12 information-security-"https:"-"https:"-"https:" PhD positions at University of Plymouth
Sort by
Refine Your Search
-
Topological Data Analysis for Multimodal Neuroimaging: MRI and NIRS Biomarkers of Brain Change DoS Dr Nathan Broomhead (nathan.broomhead@plymouth.ac.uk, tel.: +441752586874) 2nd Supervisor Dr Mariam
-
personal journeys and daily activities, often discouraging use. To address this, the project engages directly with PwMD and their carers to co design a fresh concept of wandering safety that protects
-
funded UDLA PhD studentship. The studentship will start on 1st October 2026. Project Description This project develops advanced simultaneous wireless information and power transfer technologies (SWIPT
-
@plymouth.ac.uk) 3rd Supervisor: Prof. Shangming Zhou (shangming.zhou@plymouth.ac.uk ) Industrial Partner: This project is partly funded by Advanced Micro Devices (AMD) . AMD is a leading global semiconductor
-
are invited for a 3.5-year EPSRC funded UDLA PhD studentship. The studentship will start on 1st October 2026. Project Description Offshore solar energy is an emerging and highly promising technology for
-
. The studentship will start on 1st October 2026. Project Description Project Aim To develop and validate an AI co-pilot software system integrating multi-modal radiomics data to enhance cancer detection speed and
-
EPSRC funded UDLA PhD studentship. The studentship will start on 1st October 2026. Project Description The project aim is to develop novel FETs and biosensors based on Graphene and 2D Materials
-
of typically 250 kHz and 2.7 V/cm. The commercial electric field system is usually supplemented with chemotherapy drugs. Pancreatic cancer patients only have a 10%, 5-year, survival rate. Little electric field
-
understanding and practical tools that can accelerate the adoption of low-carbon, nature-enhanced coastal protection worldwide. The work is particularly suited to applicants with interests in physical modelling
-
cancer deaths in the UK, and diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive subtypes. Standard first-line therapy (R-CHOP) cures many patients but ~40% are refractory